
    
      Inclusion criteria:

        -  histologically confirmed hepatic cancer without symptomatic extrahepatic manifestation.

        -  non-resectable disease or hepatic resection or ablation in between the past 8 weeks.

        -  measurable disease (at least before hepatic resection)

        -  Karnofsky performance status => 70%, or ECOG status 0-2

        -  >18 years of age

        -  life expectancy > 6 months

        -  compliance of the patient

        -  written informed consent

      Exclusion criteria:

        -  second neoplasia within the past 3 years, except for non-melanotic skin cancer,
           adequately treated Ca in situ of cervix uteri, or adequately resected second colorectal
           cancer (in patients with liver metastases of colorectal cancer)

        -  symptomatic extrahepatic disease, in particular disseminated bone metastases, brain
           metastases

        -  liver cirrhosis with portal hypertension, active hepatitis B or C, previous percutaneous
           radiotherapy of the liver

        -  active infection

        -  history of gastric or duodenal ulcer

        -  symptomatic or uncontrolled peripheral arterial occlusive disease, history of stenosis
           of the renal artery.

        -  history of dilatative cardiomyopathy, vitium of mitral or aortic valve, persisting
           foramen ovale, atrial fibrillation

        -  artificial heart valve or vascular

        -  history of diabetic microangiopathy

        -  uncontrolled hyperthyriodism

        -  other severe concomitant disease (heart failure >NYHA 2Â°, respiratory failure, renal
           failure >stage2, liver failure (TPZ <50%).

        -  inherited or acquired immunodeficiency syndrome

        -  contraindication against 5-FU

        -  pregnancy and nursing, no contraception

        -  limited contractual capability.

      After enrollment, an a port catheter catheter system is interventionally implanted into the
      hepatic artery and the patient is scheduled for regional chemotherapy according one out of 8
      pre-defined chemotherapy schedules. All regimens are based on 5-fluorouracil and leucovorin,
      and optionally contain intraarterial mitomycin, oxaliplatin, or additional intravenous
      irinotecan.

      Patients are followed up and evaluated for primary and secondary endpoints. After the
      inclusion of 50 patients treated and follow up at our institution, the study population has
      been extended to 100 patients in 8/2004.
    
  